Analyst Ratings For Aduro BioTech Inc (NASDAQ:ADRO)
Today, HC Wainwright reiterated its Buy rating on Aduro BioTech Inc (NASDAQ:ADRO) with a price target of $8.30.
There are 6 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.
The current consensus rating on Aduro BioTech Inc (NASDAQ:ADRO) is Buy with a consensus target price of $9.86 per share, a potential 258.55% upside.
Some recent analyst ratings include
- 12/19/2018-Aduro BioTech Inc (NASDAQ:ADRO) had its Buy rating reiterated by HC Wainwright with a $8.30 price target
- 10/31/2018-Aduro BioTech Inc (NASDAQ:ADRO) had its Buy rating reiterated by Cowen
- 10/3/2018-Aduro BioTech Inc (NASDAQ:ADRO) had its Buy rating reiterated by William Blair
- 3/5/2018-Aduro BioTech Inc (NASDAQ:ADRO) had its Buy rating reiterated by Cantor Fitzgerald with a $15.00 price target
- On 12/12/2018 Elsas Andrea Van, Insider, sold 2,171 with an average share price of $2.93 per share and the total transaction amounting to $6,361.03.
- On 12/12/2018 Jennifer Lew, CFO, sold 1,035 with an average share price of $2.93 per share and the total transaction amounting to $3,032.55.
- On 12/12/2018 Stephen T Isaacs, CEO, sold 5,829 with an average share price of $2.93 per share and the total transaction amounting to $17,078.97.
- On 11/20/2018 Blaine Templeman, Insider, sold 843 with an average share price of $2.91 per share and the total transaction amounting to $2,453.13.
- On 9/24/2018 Blaine Templeman, Insider, sold 10,262 with an average share price of $5.81 per share and the total transaction amounting to $59,622.22.
- On 9/13/2018 Blaine Templeman, VP, sold 6,056 with an average share price of $6.50 per share and the total transaction amounting to $39,364.00.
- On 9/13/2018 Jennifer Lew, CFO, sold 5,623 with an average share price of $6.50 per share and the total transaction amounting to $36,549.50.
About Aduro BioTech Inc (NASDAQ:ADRO)
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Recent Trading Activity for Aduro BioTech Inc (NASDAQ:ADRO)
Shares of Aduro BioTech Inc closed the previous trading session at 2,76 +0,30 11,94 % with 2.9 shares trading hands.
